ArticleRevista da Associacao Medica Brasileira (1992)2025
Is the use of vaginal progesterone a factor in pregnant women diagnosed with gestational diabetes mellitus?
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the effect of vaginal progesterone used to prevent spontaneous preterm birth in the development of gestational diabetes mellitus.
methodsThis is a cross-sectional study that investigated pregnant women aged 18-39 years. The study participants underwent a 2-h, 75-g oral glucose tolerance test at 24 and 28 weeks of gestation. A total of 3,066 patients met the inclusion criteria, and 418 were diagnosed with gestational diabetes mellitus based on at least one abnormal plasma glucose value during screening. The remaining 2,648 patients, who had normal plasma glucose levels, were classified as the control group. The two groups were compared based on various factors, including age, parity, pre-pregnancy body mass index, smoking status, gestational age, and use of vaginal progesterone.
resultsThe use of vaginal progesterone was statistically significant at a higher rate in the gestational diabetes mellitus group compared to the control group (22.0 vs. 16.0%; p=0.002). The mean duration of vaginal progesterone use was 53.4±14.6 days (ranging from 28 to 90 days), and this duration was statistically significantly longer in the gestational diabetes mellitus group (59.9±14.8 vs. 52.0±14.2; p<0.001).
conclusionThe findings suggest that the use of vaginal progesterone may increase the risk of gestational diabetes mellitus, and the risk appears to rise with the duration of progesterone use. It is important to consider that patients on prolonged vaginal progesterone, particularly those started early in pregnancy, may be at increased risk of diabetes. Therefore, it may be advisable to repeat the oral glucose tolerance test performed at 24-28 weeks in the following weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.